Drug Delivery Business

  • Discovery
    • Technology
  • Research & Development
  • Preclinical Trials
  • Clinical Trials
  • Policy
  • Contract Services
  • Diagnostics

Propeller raises $20m and prepares to extend reach beyond digital inhalers

May 31, 2018 By Sarah Faulkner Leave a Comment

Propeller HealthDigital therapeutics company Propeller Health and drug-delivery device-maker Aptar Pharma are teaming up, yet again, to develop an array of connected drug-delivery devices.

The pair has worked together in the past – in 2016, the companies launched the world’s first fully-integrated connected metered dose inhaler.

Now, they hope to create a platform of digital therapeutics, including inhaled, injectable, nasal and dermal drug-delivery systems. The companies didn’t elaborate on the specifics, but the partnership represents a step outside of Propeller’s traditional focus on respiratory disease.

“Propeller draws on nearly a decade of experience pioneering digital respiratory medicines and putting them to work in healthcare organizations around the world,” co-founder & CEO David Van Sickle said in prepared remarks. “We’re excited to expand our relationship with Aptar and apply our expertise to new diseases. Our end-to-end infrastructure enables fast, flexible and secure development and commercialization of digital medicines.”

“Aptar Pharma has been providing innovative drug delivery systems for nearly 50 years, helping billions of patients around the world. Today, we are excited to broaden our offerings as we continue this journey towards improved patient care and clinical outcomes by growing our partnership with Propeller Health, the leader in their field of digital therapeutics,” Salim Haffar, president of Aptar Pharma, added.

According to the terms of the deal, Propeller and Aptar plan to co-market the platform of connected devices. Propeller is responsible for managing digital services and Aptar will manage device development, manufacturing and supply chain.

On top of the expanded partnership, Aptar contributed $10 million to Propeller’s $20 million financing round. Other investors included Safeguard Scientifics, 3M Ventures and Hikma.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Respiratory Tagged With: aptarpharma, Propeller Health

IN CASE YOU MISSED IT

  • Phillips-Medisize is expanding in Wisconsin
  • Cash-strapped Aradigm declares bankruptcy
  • Medtronic: Patient deaths left out of paclitaxel-coated balloon analysis
  • Teva aims for 25% of U.S. EpiPen market by 2020
  • Medtronic wins FDA’s breakthrough status for closed-loop insulin system

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS